Wockhardt acquires CP Pharma in L11M deal

20 July 2003

Indian drugmaker Wockhardt has acquired UK-based CP Pharmaceuticals for L10.9 million ($17.9 million) cash in a deal which grows the Indian firm's UK market presence, as well as creating a larger manufacturing base from which to expand its business into other European markets.

CP has four main business areas including a branded portfolio of drugs sold in the hospital setting, generic products, contract manufacturing and exports. The acquisition of the Wrexham, Wales-headquartered firm will bring Wockhardt's annual UK sales to around L50 million, noted the company.

Commenting on the deal, Wockhardt chairman Habil Khorakiwala said he had acquired a "leading player in the UK generic space," adding: "Wockhardt has global strengths in manufacturing and research which we will leverage to drive CP's growth in the UK and Europe."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight